Abstract: A location-based service includes detecting the relative motion of an on-site resource, such as a shopping cart, in addition to detecting the absolute position of the on-site resource, and displaying information on the on-site resource. The displayed information is based upon the detected relative motion and the detected absolute position. The relative motion is tracked and a position on a floor plan is deduced. This deduced position is adjusted, for example, synchronized or reset, as a function of and in response to the detected absolute position.

Abstract: New 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives having the chemical structure of general formula (I), and pharmaceutically acceptable salts thereof are disclosed, as well as processes for their preparation and to pharmaceutical compositions containing them and their use in the treatment, prevention or suppression of pathological conditions, diseases and disorders susceptible of being improved by inhibition of PDE7.

Abstract: A location-based service includes detecting the relative motion of an on-site resource, such as a shopping cart, in addition to detecting the absolute position of the on-site resource, and displaying information on the on-site resource. The displayed information is based upon the detected relative motion and the detected absolute position. The relative motion is tracked and a position on a floor plan is deduced. This deduced position is adjusted, for example, synchronized or reset, as a function of and in response to the detected absolute position.

Abstract: A system receives AC power from an Uninterruptable Power Supply (UPS) on an AC power cable. The AC power cable couples a primary AC line voltage or a switched secondary AC line voltage depending on the quality of the primary AC line voltage. The UPS has a modulating circuit with a power line carrier protocol that receives a power down signal from the UPS if the primary AC line voltage indicates that the system should power down in a controlled manner or take other power down actions. The modulating circuit generates a modulated power down signal that is coupled to the AC power cable. The system has a corresponding demodulating receiving circuit with the power line carrier protocol that receives the modulated power down signal and regenerates the power down signal. The power down signal is coupled to circuitry in the system that initiates power down sequencing options.

Abstract: A location-based service includes detecting the relative motion of an on-site resource, detecting the absolute position of the on-site resource, and tracking the position of the on-site resource. The position is tracked by deriving a deduced position based on the detected relative motion and adjusting the deduced position as a function of and in response to the detected absolute position. According to one embodiment, the on-site resource can be a shopping cart and the tracking includes recording a travel pattern of the shopping cart as it moves through a site floor plan such that the travel pattern is reproducible. Preferably, the recorded travel pattern includes travel patterns within an aisle in the site floor plan such that the recorded patterns include travel along the length of the aisle and travel having components which are perpendicular to the length of the aisle.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-?] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.

Abstract: A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahedra-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4?,3?-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both in vivo and in vitro tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with caffeine and an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: New analgesic compounds, which are prepared by the hydrolysis of N-acylated 4-hydroxyphenylamine derivatives, their synthesis and pharmaceutical compositions containing them are disclosed. These compounds surprisingly possess high analgesic activity with little hepatotoxic effect, making them more useful than conventional non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of chronic pain.

Abstract: A system receives AC power from an Uninterruptable Power Supply (UPS) on an AC power cable. The AC power cable couples a primary AC line voltage or a switched secondary AC line voltage depending on the quality of the primary AC line voltage. The UPS has a modulating circuit with a power line carrier protocol that receives a power down signal from the UPS if the primary AC line voltage indicates that the system should power down in a controlled manner or take other power down actions. The modulating circuit generates a modulated power down signal that is coupled to the AC power cable. The system has a corresponding demodulating receiving circuit with the power line carrier protocol that receives the modulated power down signal and regenerates the power down signal. The power down signal is coupled to circuitry in the system that initiates power down sequencing options.

Abstract: The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency and are free from antipyretic activity, do not suppress blood coagulation, and have little hepatotoxic effect.

Abstract: A new method to synthesize the platelet-activating factor antagonist which is a derivative of thienotriazolodiazepene, tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methosy-4 phenyl carbamoyl)-9 pyrido[4,3-:4,5] thieno[3,2-f] triazolo-1,2,4 [4,3-&agr;] diazepine-1,4] (1) is disclosed. The compound synethesized by this new method has been designated “LAU-8080” which has the same structure as the compound currently named in the literature as “BN-50730.” LAU-8080 was shown to prevent photoreceptor cell death, inhibit pathological neovascularization in the retina, and minimize the loss of neurons due to ischemic-reperfusion damage due to stroke. Thus LAU-8080 can be used to treat the retinal diseases of age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy. It can also be used to minimize the neuronal damage due to stroke.

Abstract: We have synthesized a series of new derivatives of (2-azinylamino) quinone, that have the general formula shown below. Several compounds of this new series of derivatives have been shown to be inhibitors of 5-lipoxygenase, with minimal or no effect on cycloxygenase-1 and 2-(COX-1 and COX-2) activity. where: A is N, CH, or, CCl; B is N, CH, CCH3, or Cph; X is H, Cl, Br, or I; Y is H, or CH3; R1 is H, CH3, OCH3, or Ph; and R2 is H, CH3, OCH3, or Ph; or R1—R2 is (CH═CH)2; and R3 is H or CH3.

Abstract: The present invention is concerned with new pyridine double esters of formula (I), their acids, and pharmaceutically acceptable salts. These compounds can be obtained by oxydation of the corresponding 1,4-dihydropyridines, and they are useful as cardioprotective agents in pharmaceutical compositions.

Abstract: A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahedra-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4′,3′-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both in vivo and in vitro tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.

Abstract: The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.

Abstract: The present invention relates to a series of new N-acylated 4-hydroxyphenylamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3(2H)-one 1,1-dioxide group, of formula I: ##STR1## in which n is a number from 1 to 5, and to processes for preparing these derivatives and to pharmaceutical compositions containing said derivatives; these compounds possess high analgesic activity free from antipyretic activity, and they display little hepatotoxic effect.

Abstract: Novel quaternary ammonium salts of general formula (I) ##STR1## wherein: R is a saturated or unsaturated, linear or branched alkyl radical of C.sub.1 to C.sub.8.R' is a saturated or unsaturated, linear or branched alkyl radical of C.sub.1 to C.sub.12, or a benzyl radical.n is a number equal to 2 or 3.X.sup..theta. is a halogenide anion, such as Cl.sup..theta., Br.sup..theta., I.sup..theta., are used as phase transfer catalysts, in heterogeneous ionic reactions wherein the reagents are in different phase and have different polarity.